Richard A. Young - 11 Sep 2025 Form 4 Insider Report for Camp4 Therapeutics Corp (CAMP)

Reporting relationship: Director
Issuer ticker: CAMP
Reported as of: 11 Sep 2025
Net transaction value: +$24,999
SEC form: 4
Accepted by SEC: 11 Sep 2025, 16:22:32 UTC
Prior SEC filing: 27 Jun 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Josh Mandel-Brehm, as Attorney-in-Fact

Key filing fact

Richard A. Young filed Form 4 for Camp4 Therapeutics Corp (CAMP) on 11 Sep 2025.

Key facts

This page summarizes Richard A. Young's Form 4 filing for Camp4 Therapeutics Corp (CAMP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Sep 2025, 16:22.

Change

Previous filing in this sequence was filed on 27 Jun 2025.
Current net transaction value: +$24,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001490283 Primary reporting owner

Young Richard A

Relationship: Director
Address: C/O CAMP4 THERAPEUTICS CORPORATION, ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL., CAMBRIDGE
Signature: /s/ Josh Mandel-Brehm, as Attorney-in-Fact
Signature date: 11 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAMP transaction

Common Stock

Purchase

Transaction value: $24,999
Shares: +15,151
Change %: +9.8%
Price: $1.65
Shares after: 170,010
Date: 11 Sep 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.